True North Labs

Author: labstruenorth@gmail.com

  • New Phase 2 Trial Launches for VS-7375 in KRAS G12D-Mutated Colorectal Cancer

    New Phase 2 Trial Launches for VS-7375 in KRAS G12D-Mutated Colorectal Cancer

    A new Phase 2 clinical trial has been initiated to study VS-7375, an investigational therapy designed to target KRAS G12D-mutated metastatic colorectal cancer. This mutation represents a significant subset of colorectal cancer cases, and the KRAS gene has historically been considered one of the more challenging oncology targets to address with precision therapies. The launch of this trial reflects continued progress in the field of targeted cancer treatment.

    According to the study listing on ClinicalTrials.gov, researchers will evaluate the safety and efficacy of VS-7375 both as a standalone treatment and in combination with other established therapies, including cetuximab, panitumumab, and the chemotherapy regimen mFOLFOX. This combination-focused approach is notable because it allows investigators to explore how VS-7375 might work alongside existing standard-of-care options, potentially expanding treatment strategies for patients who currently have limited targeted options for this particular mutation.

    Phase 2 trials mark an important step in the drug development process, typically following earlier studies that establish preliminary safety and dosing information. Advancing to this stage suggests that VS-7375 has shown enough early promise to warrant further investigation in a broader patient population. For individuals and families affected by KRAS G12D-mutated colorectal cancer, the initiation of this trial offers a meaningful reason for cautious optimism, as it represents an additional avenue of research aimed at improving outcomes for a hard-to-treat cancer subtype.

    The peptide and targeted therapy research space continues to evolve rapidly, with KRAS-directed treatments representing one of the more closely watched areas of oncology innovation in recent years. Trials like this one contribute valuable data that can help shape future treatment guidelines and expand the toolkit available to oncologists treating metastatic colorectal cancer. As enrollment and data collection proceed, the results will be closely watched by both the medical community and patient advocacy groups.

    True North Labs will continue to monitor developments related to this and other promising peptide and targeted therapy research as new information becomes available. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

  • New Clinical Trial Launches to Evaluate COYA 302 for ALS Treatment

    New Clinical Trial Launches to Evaluate COYA 302 for ALS Treatment

    A new clinical trial called ALSTARS is set to begin evaluating COYA 302, an investigational biologic therapy, as a potential treatment option for adults living with Amyotrophic Lateral Sclerosis (ALS). The study will be conducted at 20 to 25 sites across the United States and Canada, offering more patients access to cutting-edge research close to home.

    COYA 302 combines two components: low dose interleukin-2 (LD IL-2) and DRL_AB, a biosimilar candidate for abatacept. Together, these are designed to work through a dual immunomodulatory mechanism, aiming to boost the anti-inflammatory activity of regulatory T cells while also calming inflammation driven by activated monocytes and macrophages. This approach reflects a growing scientific interest in addressing the immune and inflammatory components that may contribute to ALS progression.

    The trial is structured thoughtfully, with participants randomly assigned to one of two COYA 302 dosing regimens or a placebo group during an initial 24-week double-blind period. Importantly, those who complete this phase will have the opportunity to continue into a 24-week extension period where they will receive one of the active COYA 302 regimens, giving more participants a chance to experience the investigational therapy over time.

    Researchers will track meaningful, well-established measures of ALS progression, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament light chain levels, maximal inspiratory pressure, and slow vital capacity. These outcome measures are widely used in ALS research and should provide valuable insight into whether COYA 302 can meaningfully impact disease trajectory, in addition to standard safety monitoring throughout the study.

    For the ALS community, every new well-designed clinical trial represents a step forward. ALS remains a challenging condition with limited treatment options, and studies like ALSTARS that explore novel immunomodulatory approaches offer hope for expanding the therapeutic toolkit available to patients and clinicians. As enrollment moves forward across multiple sites, the coming months and years of data collection will help clarify whether this combination therapy can offer real benefit to those affected by this disease.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Study of COYA 302 for the Treatment of ALS

  • TearSolutions’ NK Peptide Therapy Earns Two Special FDA Designations

    TearSolutions’ NK Peptide Therapy Earns Two Special FDA Designations

    TearSolutions, a biotechnology company focused on ophthalmic peptide therapeutics, has announced that the U.S. Food and Drug Administration has granted two special designations to its investigational NK peptide therapy. While the specific designations can vary by program, such regulatory recognitions typically signal that the FDA sees meaningful potential in a therapy to address an unmet medical need, and they often come with benefits like enhanced communication with the agency and, in some cases, an expedited review pathway.

    The NK peptide therapy is being developed as a potential treatment for individuals dealing with tear-deficiency conditions, an area where patients have historically had limited options beyond artificial tears and a small number of prescription therapies. Peptide-based approaches like this one aim to work with the body’s natural signaling pathways to help support tear production and ocular surface health, rather than simply providing temporary lubrication.

    Receiving dual FDA designations is a notable vote of confidence for a peptide-based ophthalmic therapy still in development. For patients living with chronic dry eye or related tear-deficient conditions, this kind of regulatory milestone can be an encouraging sign that new, more targeted treatment options may eventually become available. It also reflects a broader trend of peptide therapeutics gaining traction in specialty areas like eye care, where precision and safety are especially important.

    For TearSolutions, these designations may help streamline future interactions with the FDA as the company continues to advance its clinical development program. While there is still a path ahead before any therapy reaches patients, this kind of regulatory support is often an important early indicator that a treatment is being taken seriously as a potential addition to the therapeutic landscape for eye health.

    This news is a promising example of how peptide science continues to open new doors in specialized areas of medicine. As always, developments like this are worth watching, and patients interested in emerging treatments should stay in touch with their eye care providers for updates.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA grants TearSolutions’ NK peptide therapy two FDA designations – Glance by Eyes On Eyecare

  • FDA Signals Move to Ease Restrictions on Certain Peptides

    FDA Signals Move to Ease Restrictions on Certain Peptides

    In a development that has caught the attention of the peptide research and biotech community, the U.S. Food and Drug Administration appears to be moving toward easing restrictions on certain peptide-based compounds. According to reporting from BioPharma Dive, regulators are reconsidering the current framework that governs how some peptides are classified and accessed, a shift that could have wide-reaching implications for manufacturers, researchers, and patients alike.

    Peptides have long occupied a unique space in the world of therapeutics — smaller and more targeted than traditional biologics, yet often more complex to regulate than simple small-molecule drugs. Over the past several years, many peptide compounds have faced tightened oversight, in part due to concerns about compounding practices and quality control. A move by the FDA to ease certain restrictions suggests a recalibration of that approach, potentially reflecting growing confidence in manufacturing standards and a clearer understanding of how specific peptides should be regulated.

    For the broader peptide field, this kind of regulatory flexibility can be a meaningful catalyst. Easier pathways often translate into more opportunities for legitimate manufacturers to bring well-characterized products to market, more resources devoted to quality research, and potentially expanded access for patients and practitioners who rely on peptide therapies. It may also encourage renewed investment in peptide research and development, as companies gain more clarity on the regulatory road ahead.

    While the specifics of which peptides may be affected and the exact nature of the eased restrictions remain to be fully detailed, the overall direction is encouraging for an industry that has been eager for more predictable and supportive regulatory guardrails. A more balanced regulatory environment — one that still prioritizes safety and quality but reduces unnecessary friction — could help legitimate innovation flourish while continuing to protect consumers.

    As this story develops, True North Labs will continue to monitor updates from the FDA and share further details as they become available. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA moves toward easing restrictions on certain peptides – BioPharma Dive

  • Oral GLP-1 Contender: CU Anschutz Explores Orforglipron for Weight Loss

    The University of Colorado Anschutz Medical Campus is taking part in clinical trial research on orforglipron, an experimental oral medication that works on the same GLP-1 pathway as popular injectable weight-loss drugs. For patients who have been hesitant about needles or who simply prefer the convenience of a pill, this line of research represents an exciting potential expansion of options in the growing field of metabolic health treatments.

    GLP-1 receptor agonists have transformed the conversation around weight management and blood sugar control in recent years, but until now most of the highest-profile options have required injections. An effective oral version could make this class of treatment more accessible and appealing to a broader range of patients, including those in areas with limited access to injectable therapies or those who have avoidance around self-injection. Academic medical centers like CU Anschutz play a critical role in this kind of research, helping to generate the rigorous, independent data needed to understand how new formulations perform in real-world patient populations.

    Participating in a clinical trial also gives patients at CU Anschutz early access to emerging therapies under close medical supervision, while contributing to the broader scientific understanding of how oral GLP-1 medications might work for weight loss. This kind of institutional involvement is a positive sign for the pipeline of obesity and metabolic treatments, suggesting that researchers continue to look for ways to make effective therapies simpler and more convenient to use.

    The broader significance here is that innovation in drug delivery format, not just drug chemistry, can meaningfully improve how many people are able to benefit from a treatment. If oral GLP-1 options continue to show promise in trials like this one, it could mean more choices for people working with their healthcare providers on weight and metabolic health goals, and potentially easier long-term adherence to treatment plans.

    As with any investigational medication, orforglipron is still undergoing study, and its safety and effectiveness profile will continue to be evaluated through the clinical trial process. This article is for informational purposes only and is not medical advice; anyone interested in learning more about GLP-1 therapies or clinical trial participation should speak with a qualified healthcare provider.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: What Is Orforglipron? Inside a CU Anschutz Clinical Trial for a New Oral GLP-1 Weight-Loss Drug – University of Colorado Anschutz

  • FDA Advisory Panel Backs Continued Access to Compounded Peptides

    An FDA advisory committee has voted in favor of allowing certain peptides to continue to be prepared by compounding pharmacies, even though these specific formulations have not gone through the traditional FDA drug approval process. The vote, while narrow, represents a meaningful outcome for patients and clinicians who have come to rely on compounded peptide therapies as part of their treatment options.

    Compounding pharmacies play a unique role in the healthcare system, allowing licensed pharmacists to prepare personalized medications for patients with specific needs that may not be met by commercially available drugs. For peptides in particular, compounding has offered a pathway for practitioners to access promising compounds while the broader regulatory and research infrastructure around these molecules continues to develop.

    This advisory panel decision suggests a recognition of the value that compounded peptides can offer, whether that’s flexibility in dosing, access to formulations not yet available through traditional pharmaceutical channels, or support for individualized treatment plans developed between patients and their healthcare providers. For the peptide community—including researchers, clinicians, and patients who have found benefit from these therapies—this vote signals continued room for innovation and access within the current regulatory framework.

    It’s worth noting that FDA advisory panel votes are recommendations, not final rules, and the agency will weigh this input as it continues to refine its approach to peptide compounding oversight. Nonetheless, this outcome is an encouraging sign that regulators are considering pathways to maintain access rather than simply restricting it, which many in the field have advocated for as the science around peptides continues to mature.

    As this regulatory conversation evolves, it reflects a broader trend of thoughtful engagement between health authorities and the growing peptide therapeutics space. This is for informational purposes only and not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides – STAT

  • FDA Advisory Panel Backs Easing Restrictions on Six Popular Peptides

    In a development that could reshape access to a popular category of therapeutic compounds, an FDA advisory committee has expressed support for easing restrictions on six specific peptides. The advisory panel’s recommendation marks a meaningful step forward for peptides that have generated significant interest among both clinicians and patients for their potential roles in areas like recovery, metabolic support, and overall wellness.

    Advisory committees play a crucial role in the FDA’s regulatory process, offering expert guidance that often shapes the agency’s final decisions. While the FDA is not obligated to follow every committee recommendation, these panels carry substantial weight, and a favorable vote frequently signals that regulatory movement may be on the horizon. For the peptide community, this show of support suggests growing recognition within scientific and regulatory circles of the value these compounds may offer.

    Peptides have increasingly captured attention in recent years as researchers continue to explore their diverse applications, from supporting muscle recovery to potentially aiding metabolic health. However, regulatory uncertainty has sometimes complicated access for both compounding pharmacies and the practitioners who work with patients interested in peptide-based approaches. A move toward easing restrictions could help clarify pathways for legitimate, quality-controlled access to these compounds, benefiting patients who rely on knowledgeable providers.

    The specific next steps will depend on how the FDA proceeds following this advisory input. Typically, the agency will weigh the committee’s feedback alongside other regulatory considerations before making a final determination. For those following the peptide space, this is an encouraging sign that regulatory frameworks may be evolving to better accommodate the growing body of interest and, potentially, evidence supporting responsible peptide use.

    At True North Labs, we’ll continue monitoring this story as it develops, keeping our readers informed about what these regulatory shifts could mean for the broader peptide landscape. As always, changes like these underscore the importance of working within established medical and regulatory guidelines when considering any peptide-related approach.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next – CNN

  • Tesamorelin: A Standout Example of an FDA-Approved Peptide Success Story

    Tesamorelin: A Standout Example of an FDA-Approved Peptide Success Story

    Tesamorelin holds a distinctive place in the world of peptide science: it is one of the relatively few peptides to have earned full FDA approval, giving it a level of regulatory validation that many other investigational peptides have yet to achieve. As a growth hormone-releasing hormone (GHRH) analog, tesamorelin works by stimulating the body’s own natural growth hormone production pathways rather than introducing synthetic growth hormone directly, an approach that reflects a broader shift toward more physiologically-guided peptide therapies.

    What makes tesamorelin particularly noteworthy for peptide researchers and clinicians is its documented path through clinical trials and regulatory review. Unlike many peptides that remain in early research or compounding-pharmacy gray areas, tesamorelin’s approval process means it has been subject to the rigorous safety and efficacy standards the FDA requires. This track record serves as a useful reference point for how peptide-based therapies can successfully navigate the regulatory system when supported by solid clinical evidence.

    Its unique mechanism, working upstream to encourage the body’s natural hormone signaling rather than overriding it, has also made tesamorelin a frequently cited example in discussions about the future direction of peptide therapeutics. Researchers studying growth hormone pathways often point to it as a model for how targeted, receptor-specific peptides can be designed with a clear physiological rationale.

    For the peptide research community, tesamorelin’s story is an encouraging signal. It demonstrates that with proper trial design and regulatory diligence, peptide-based approaches can move from promising laboratory concepts to approved clinical tools. As interest in GHRH analogs and related peptides continues to grow, tesamorelin stands as a benchmark for what a well-supported, thoroughly vetted peptide therapy can look like.

    This article is for informational purposes only and is not intended as medical advice. Anyone interested in learning more about tesamorelin or peptide therapies should consult a qualified healthcare provider.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Tesamorelin Explained: The FDA-Approved GHRH Analog That Sits in a Unique Position in Peptide Research – Haute Living

  • US Health Panel Eases Restrictions on Popular Peptides, Expanding Access

    A U.S. health advisory panel has taken a notable step toward expanding access to a group of peptides that have become widely discussed online for their potential wellness and recovery benefits. The panel’s decision to ease previous restrictions signals a shift toward recognizing the growing interest in these compounds among both patients and healthcare providers.

    Peptides have surged in popularity in recent years as more people explore options for recovery, longevity, and general wellness support. Until now, many of these compounds faced tighter regulatory hurdles that limited their availability through compounding pharmacies, which play a key role in preparing personalized medications. By loosening these restrictions, the panel is effectively acknowledging both the demand for these peptides and a reassessment of how they should be regulated moving forward.

    This move could make it easier for compounding pharmacies to legally prepare and distribute certain peptides, potentially improving access for people who have sought them through less regulated channels. Greater oversight through legitimate pharmacy channels can be a meaningful step toward ensuring more consistent quality and manufacturing standards, compared to the unregulated online markets where many consumers have turned in the past.

    Industry observers see this development as part of a broader trend of regulators adapting to fast-evolving interest in peptide-based products. As research into peptides continues to expand across areas like recovery, metabolic health, and healthy aging, decisions like this one may pave the way for more structured study and safer, more transparent access in the future.

    While the panel’s action represents a positive shift toward accommodating public interest and pharmacy-based access, it’s still important for anyone considering peptide use to consult with a qualified healthcare provider. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: US health panel loosens restrictions for controversial peptides popular online – BBC

  • Lilly Advances Toward FDA Approval for Retatrutide, a Promising Triple-Action Obesity Peptide

    Lilly Advances Toward FDA Approval for Retatrutide, a Promising Triple-Action Obesity Peptide

    Eli Lilly has announced plans to seek FDA approval for retatrutide, an investigational peptide designed to target three key metabolic hormone receptors simultaneously, based on encouraging new clinical trial data. The move marks a significant step forward in the growing field of peptide-based therapies for weight management and metabolic health.

    Retatrutide belongs to a novel class of compounds that act on GIP, GLP-1, and glucagon receptors together, an approach researchers believe may offer more comprehensive metabolic benefits than therapies that target a single pathway. The peptide has been closely watched by the scientific community as one of the more advanced multi-receptor candidates in development, building on the momentum of earlier GLP-1-based treatments that have already reshaped obesity care.

    The decision to move toward regulatory submission reflects growing confidence in the drug’s data package, suggesting that the compound has performed well enough in trials to support a formal review by health authorities. For patients and clinicians, an FDA submission is a meaningful milestone, representing the transition from research-stage development to the possibility of a new treatment option becoming available under medical supervision.

    This development is part of a broader wave of innovation in peptide therapeutics, where multi-target designs are increasingly seen as a way to potentially improve outcomes for people managing obesity and related metabolic conditions. If approved, retatrutide would add to a growing toolkit of peptide-based options that give physicians more ways to tailor treatment to individual patient needs.

    While the regulatory process still lies ahead, the announcement underscores the pace at which peptide science is advancing and highlights the continued investment from major pharmaceutical companies in this promising area of medicine. As always, any new therapy would become available only through appropriate medical channels following regulatory review.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Lilly, with new data, to seek FDA approval of obesity drug retatrutide – BioPharma Dive